Patients from 22+ countriesPlan your visit →
lutetium-therapy
Comparing Options · 4 Sept 2026

When Somatostatin Analogues Are Enough for GEP-NET

If you have a GEP-NET and your oncologist has placed you on octreotide or lanreotide, you may wonder whether PRRT is also needed. For many patients with stable, slow-growing, well-differentiated tumors, somatostatin analogues may be the right treatment for now.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 4 Sept 2026
When Somatostatin Analogues Are Enough for GEP-NET

If your oncologist started you on octreotide or lanreotide for a gastroenteropancreatic neuroendocrine tumor (a GEP-NET), you might wonder if you need PRRT too. PRRT stands for peptide receptor radionuclide therapy. It uses lutetium Lu-177 dotatate (sold as Lutathera) to find and kill tumor cells in the body. Many GEP-NET patients don't need it. Some can wait.

This article is for patients on the DOTATATE/PRRT treatment track - people with GEP-NETs, carcinoid tumors, midgut NETs, pancreatic NETs, and related neuroendocrine conditions. If you have prostate cancer, separate articles on this site cover the Lu-177 PSMA track.

How Do Somatostatin Analogues and PRRT Compare for GEP-NET Patients?

SSA versus PRRT: key decision factors for GEP-NET patients weighing when to escalate treatment
FactorSomatostatin Analogues (SSA)PRRT with Lu-177 Dotatate
Tumor gradeStrongest evidence in grade 1 and lower-grade 2 (Ki-67 up to about 10%)Primary evidence for grade 1 and grade 2 with positive receptor imaging; research ongoing in grade 3 NETs
Disease status on imagingFirst choice when disease is stable or very slowly progressing on CT or MRIIndicated when disease is clearly progressing despite adequate SSA therapy
Receptor imaging requirementPositive Ga-68 DOTATATE-PET supports suitability - SSAs need receptor expression to bind to tumor cellsPositive Ga-68 DOTATATE-PET with adequate uptake in target lesions is a core eligibility requirement
Symptom controlEffective for controlling flushing and diarrhea in functional NETs (carcinoid syndrome)May reduce tumor-related hormonal symptoms as tumor volume responds to treatment
How it is givenMonthly depot injection, often self-administered at homeIntravenous infusion in a nuclear-medicine center, typically 4 cycles given 8 weeks apart

SSA and PRRT belong at different points in treatment. SSAs are the first-line standard for stable, well-differentiated GEP-NETs. PRRT becomes the better option when disease worsens despite SSA therapy and somatostatin receptor uptake on imaging is still strong enough for targeting. Most patients who move to PRRT have already used SSAs for a while.

What Somatostatin Analogues Actually Do

Somatostatin is a hormone your body makes naturally. It slows certain cell activity in the gut, pancreas, and digestive system. Synthetic somatostatin analogues like octreotide (Sandostatin LAR) and lanreotide (Somatuline) copy this action.

They work in two ways for GEP-NET patients. First, they bind to somatostatin receptors on tumor cells, which slows tumor growth. Second, in functional tumors that release hormones like serotonin, they control symptoms such as flushing, diarrhea, and wheezing - together called carcinoid syndrome.

Octreotide LAR and lanreotide are long-acting forms given by injection once a month. Most patients tolerate them well over many months or years. Some patients self-inject lanreotide at home; others get their octreotide LAR dose at a clinic.

What the Clinical Trials Show

Two major phase III trials offer the strongest evidence that SSAs slow tumor growth in GEP-NET patients.

The PROMID trial tested octreotide LAR in patients with well-differentiated midgut NETs. Patients getting octreotide had a median progression-free survival of 14.3 months, versus 6 months for those getting placebo. That's a real delay in tumor growth from a monthly injection alone. You can read more about this and other NET landmark studies in this review of GEP-NET clinical trials at PubMed Central.

The CLARINET trial tested lanreotide in non-functional enteropancreatic NETs, including both pancreatic and midgut primary tumors. The hazard ratio for disease progression or death was 0.47 favoring lanreotide over placebo - meaning patients on lanreotide were about half as likely to progress at any given time. A full review of CLARINET is available at PubMed Central.

A 20-year review of somatostatin analogue use across NETs confirms their role as the main first-line treatment for well-differentiated, somatostatin-receptor-positive disease. That review is accessible at PubMed Central. These studies show that SSAs keep many patients stable for extended periods - sometimes years. The challenge is knowing when that stability is no longer enough.

When SSAs May Be the Right Treatment for Now

Your treatment team will weigh several factors when deciding whether to continue SSAs or move toward PRRT. SSAs are often the right choice when:

  • Your tumor grade is low. Tumor grade comes from the Ki-67 index in your pathology report. A Ki-67 below 3% means tumor cells are dividing very slowly. Grade 1 and lower-grade 2 NETs - roughly Ki-67 up to 10% - tend to grow slowly enough that SSAs can hold the disease stable for a long time. To understand what your grade means, see our article on what your NET pathology grade means for PRRT eligibility.
  • Your imaging shows stable disease. If the most recent CT or MRI shows no new lesions and no meaningful growth in existing ones compared with the prior scan, SSAs are working. Stable disease is not a cure, but it is a recognized treatment goal in GEP-NET management. Many patients stay stable for two years or more on SSAs alone.
  • Your symptoms are well controlled. For functional tumors, if flushing and diarrhea are manageable on your current SSA dose and schedule, there's no urgent need to escalate. Quality of life matters alongside the imaging result.
  • Your tumor burden is limited. Patients with fewer or smaller metastases - or lower liver involvement - may have more time before a more intensive approach is needed. Your care team considers both the size and the speed of the disease.
  • Other health factors make PRRT more complex right now. Kidney function, bone marrow reserve, and other medical conditions all affect PRRT suitability. If SSAs are holding the disease steady, your team may appropriately delay PRRT until the benefit clearly outweighs the risk.

Here's the key point: more treatment isn't always better. If SSAs are keeping your tumor stable and your quality of life good, continuing them is a sound clinical decision.

Signs That the Picture May Be Changing

GEP-NETs can progress over time. Even well-differentiated tumors can grow. Your oncologist will monitor you regularly, and certain findings may signal that escalation is worth discussing.

  • Growth on imaging. New lesions or measurable enlargement of existing ones on your CT, MRI, or Ga-68 DOTATATE PET scan shows that SSAs are no longer controlling the disease well enough.
  • Harder-to-control symptoms. If flushing, diarrhea, or other hormonal symptoms are getting worse despite your current dose - or if you need rescue doses of short-acting octreotide more often - disease activity is likely increasing.
  • Rising tumor markers. Chromogranin A (CgA) is a blood marker used in NET monitoring. A persistent rise in CgA, especially with imaging changes, is a signal worth discussing promptly.
  • Grade change on re-biopsy. In some cases, a repeat biopsy shows a higher Ki-67 index than before. This is not common, but when it happens it can change the recommended treatment approach.

If any of these patterns appear, PRRT becomes worth discussing sooner. The NETTER-1 phase III trial showed that lutetium Lu-177 dotatate led to longer progression-free survival than high-dose octreotide LAR in patients with progressive, somatostatin-receptor-positive midgut NETs. The National Cancer Institute summarized the evidence at cancer.gov. Our article on when Lu-177 DOTATATE can wait for grade 1 NET goes deeper into the decision framework for different grade scenarios.

Managing Life on Long-Term SSA Therapy

If SSAs are your current treatment, there are practical things to know about the longer term.

Imaging is typically repeated every three to six months. Blood tests - including CgA, liver and kidney function, and sometimes a 24-hour urine 5-HIAA - happen at regular intervals. This schedule catches any change in disease early, before it becomes harder to manage.

Some patients on long-term octreotide or lanreotide develop gallstones, since SSAs can slow gallbladder emptying. This is usually manageable and doesn't necessarily mean stopping the medication. Blood sugar changes can also occur, particularly in patients with pancreatic primary tumors, so glucose monitoring is part of routine care.

Some patients on extended SSA therapy notice fatigue or mild changes in nutrient absorption. If you're concerned about nutritional support during a prolonged treatment course, ask your care team to check vitamin D and B12 levels. Talk with your team about any nutritional questions you have.

The Neuroendocrine Tumor Research Foundation (NETRF) provides resources for patients living with GEP-NETs. Their site at netrf.org has patient guides, clinical trial news, and practical information for daily life with a neuroendocrine tumor.

Getting a Second Opinion on Your Treatment Plan

If you're unsure whether to continue SSAs or want an independent review of whether PRRT should be on the table sooner, getting a second opinion is reasonable. Many patients who eventually have PRRT first had their scans and pathology reviewed by a nuclear-medicine specialist who assessed the Ga-68 DOTATATE PET and Ki-67 grade together.

For a deeper look at what specialists examine when assessing PRRT eligibility, see our article on what really determines PRRT eligibility - including what your Ga-68 DOTATATE PET report needs to show.

If you would like an eligibility review, the contact form at lutetium-therapy.com/contact allows you to submit your scans and request a teleconsultation. If PRRT is not the right option at this stage, the team can advise on what other options to discuss with your oncologist.

Questions Worth Asking Your Oncologist

  • Is my disease stable on the most recent scan compared with the one before?
  • What specific imaging change would prompt you to suggest moving toward PRRT?
  • Has my Ki-67 been rechecked recently, or would a repeat biopsy give useful information?
  • How often should I be rescanned given the current pace of my disease?
  • Are there options between SSA continuation and PRRT - such as everolimus for pancreatic NETs - that might fit my case?
  • Is my current SSA dose and schedule fully optimized for my disease?

When to talk to your doctor: Contact your oncologist if you notice new or worsening symptoms - particularly increased flushing, more frequent diarrhea, unexplained weight loss, or abdominal pain. These may signal disease progression that needs prompt rescanning. Don't wait for your next scheduled appointment if symptoms worsen between visits.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Can I stay on octreotide or lanreotide if my GEP-NET is not growing?

Yes. If your imaging shows stable disease and your symptoms are controlled, continuing octreotide or lanreotide is a clinically valid choice. Stable disease is a recognized treatment goal in GEP-NET management, not a sign of failure. Your oncologist will monitor you regularly and discuss escalation only when the evidence supports it.

How do I know if somatostatin analogues have stopped working?

The clearest sign is tumor growth on imaging - new lesions or measurable enlargement of existing ones on CT, MRI, or Ga-68 DOTATATE PET. Worsening symptoms such as more frequent flushing or diarrhea despite your current dose, and a persistent upward trend in the blood marker chromogranin A (CgA), are also signals. Your oncologist tracks all of these at regular intervals.

Does PRRT replace somatostatin analogues, or do they work alongside each other?

In many cases PRRT is given alongside SSAs, particularly for functional NETs where SSAs help control hormonal symptoms like flushing and diarrhea. The SSA dose and timing are usually adjusted around PRRT cycles. After completing PRRT, some patients continue on SSAs for maintenance. Your treatment team coordinates the sequencing based on your specific situation.

What Ki-67 level suggests somatostatin analogues may be enough for now?

There is no single cut-off that applies to every patient, but grade 1 NETs (Ki-67 below 3%) and lower-grade 2 NETs (Ki-67 roughly 3% to 10%) are the populations where SSAs have the strongest evidence for disease control. Higher Ki-67 values, or a rising Ki-67 on re-biopsy, often prompt a discussion about more intensive treatment sooner. Your oncologist will interpret your grade in the context of your imaging and symptom picture together.

Can PRRT still work after years on somatostatin analogues?

Research suggests yes for many patients. Somatostatin receptor expression - confirmed by Ga-68 DOTATATE PET - is the key eligibility factor for PRRT, not the length of time spent on SSAs. Patients who have been stable on SSAs for years and then show progression often remain eligible for PRRT if their receptor uptake is still adequate and their organ function meets the criteria. A specialist review of your most recent DOTATATE-PET is the best way to confirm this.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.

GEP-NET: When Somatostatin Analogues May Be Enough | lutetium-therapy